Regulation of Signal Transduction and Role of Platelets in Liver Regeneration

Takeshi Nowatari, Kiyoshi Fukunaga, and Nobuhiro Ohkohchi

Department of Surgery, Graduate School of Comprehensive Human Sciences, University of Tsukuba, Tsukuba 305-8575, Japan

Correspondence should be addressed to Nobuhiro Ohkohchi, nokochi3@md.tsukuba.ac.jp

Received 19 April 2012; Accepted 8 June 2012

Among all organs, the liver has a unique regeneration capability after sustaining injury or the loss of tissue that occurs mainly due to mitosis in the hepatocytes that are quiescent under normal conditions. Liver regeneration is induced through a cascade of various cytokines and growth factors, such as, tumor necrosis factor alpha, interleukin-6, hepatocyte growth factor, and insulin-like growth factor, which activate nuclear factor κB, signal transducer and activator of transcription 3, and phosphatidyl inositol 3-kinase signaling pathways. We previously reported that platelets can play important roles in liver regeneration through a direct effect on hepatocytes and collaborative effects with the nonparenchymal cells of the liver, including Kupffer cells and liver sinusoidal endothelial cells, which participate in liver regeneration through the production of various growth factors and cytokines. In this paper, the roles of platelets and nonparenchymal cells in liver regeneration, including the associated cytokines, growth factors, and signaling pathways, are described.

1. Introduction

Liver regeneration is a physiopathological phenomenon of quantitative recovery from the loss of liver mass to compensate for decreased hepatic volume and impaired function [1, 2]. Although numerous studies have shown that a variety of genes, cytokines, growth factors, and cells are involved in liver regeneration, the exact mechanism of regeneration and the interaction between hepatocytes and cytokines are not fully understood [3]. Liver regeneration is a critical issue related to clinical morbidity and mortality in drug-induced liver injury and after surgery including hepectectomy or living-donor liver transplantation [4, 5]. The temporal development of the signaling pathways specifically activated during liver regeneration may be described in three phases: a priming phase, involving the transition of quiescent hepatocytes from G0 into the G1 phase of the cell cycle; a proliferation phase during which the progression of the entire hepatocyte population occurs; a termination phase during which cell proliferation is suppressed and regeneration is terminated at a defined point [6, 7]. Hepatocytes are not terminally differentiated; rather, the cells are in proliferative quiescence (the G0 phase) but can rapidly enter a cell division cycle upon stimulation [6]. The cytokines/signaling pathways and proteins that are important during the priming phase of regeneration include tumor necrosis factor alpha (TNFα)/nuclear factor κB (NFκB), interleukin-6 (IL-6)/signal transducer and activator of transcription 3 (STAT3), activator protein-1 (AP-1), and mitogen-activated protein kinase (MAPK)/extracellular signal-regulated protein kinase (ERK) [8–14]. Phosphatidylinositol 3-kinase (PI3K)/Akt is also immediately activated after hepectectomy and plays an important antiapoptotic role during liver regeneration [15]. During the proliferation phase, hepatocytes express various cell cycle proteins that guide the replication process, including hepatocyte growth factor (HGF) and epidermal growth factor (EGF) [16, 17]. Essentially, the major factors involved in the termination phase comprise transforming growth factor beta (TGFβ) and activins [6]. Seventy percent of the cell number or 80% of the liver volume is composed of hepatocytes, and the remaining cells consist of nonparenchymal cells, including Kupffer cells, liver sinusoidal endothelial cells (LSECs), hepatic stellate cells,
and lymphocytes, which are thought to play an important role in cytokine release [18]. Upon activation, Kupffer cells are reported to produce both inflammatory cytokines, such as TNFα and IL-6, and such growth factors as insulin-like growth factor (IGF)-1 [19]. LSECs have also been reported to produce IL-6 and HGF after hepatectomy and activated hepatic stellate cells mainly produce HGF [20, 21].

Platelets play pivotal roles in thrombosis and hemostasis, but an increasing variety of extrahematostatic functions of platelets have been recognized [22]. Platelets contain many growth factors, such as, platelet-derived growth factor (PDGF), vascular endothelial growth factor (VEGF), HGF, IGF, EGF and TGFβ, and some cytokines [23–29]. Furthermore, platelets play certain roles of stimulation or acceleration during hepatocyte proliferation [30]. We recently reported that platelets play a very important role in liver regeneration after hepatectomy and that HGF and IGF-1 derived from platelets are essential for hepatocyte proliferation [23, 31–33]. Platelets play a direct role in hepatocytes during liver regeneration and also a cooperative role with nonparenchymal cells in the liver [33, 34]. Kupffer cells contribute to the accumulation of platelets in the liver, which can subsequently induce liver regeneration [31, 33, 34]. Furthermore, the direct contact between platelets and LSECs induces sphingosine 1-phosphate (S1P) release from the platelets, which subsequently induces secretion of IL-6 from LSECs. The LSEC-derived IL-6 promotes DNA synthesis in hepatocytes via the STAT3 pathway [35].

Herein, we describe the cellular and molecular mechanisms of liver regeneration and the functions of some critical signaling pathways involved in hepatocyte proliferation. In particular, we focus on the roles of platelets in liver regeneration.

2. Cytokines, Growth Factors, and Signaling Pathways in Liver Regeneration

Liver regeneration occurs through the proliferation of all of the existing mature cellular populations including the hepatocytes, biliary epithelial cells, LSECs, Kupffer cells, and hepatic stellate cells. All of the cells proliferate to rebuild the lost hepatic tissue, and the hepatocytes are known to be the first cells to proliferate [36]. Hepatocytes exhibit a mitogenic response to various growth factors and cytokines, such as, HGF, IGF-1, IL-6, TNFα, EGF, TGFβ, and PDGF [1, 23]. These growth factors and cytokines lead to the subsequent activation of downstream transcription cascades, which effect the transition of the quiescent hepatocytes into the cell cycle and progression beyond the restriction point in the G1 phase [1]. The cascades also result in the activation of transcription factors and signal transduction pathways, such as, NFκB, STAT3, MAPK/ERK, PI3K/Akt, AP-1, and CCAAT/enhancer-binding protein-β, which subsequently induce hepatocyte proliferation [8–15, 37–41]. Among these transcription factors and corresponding signal transductions, the TNFα/NFκB, IL-6/STAT3, PI3K/Akt, and MAPK/ERK pathways are identified as the major cascades during the process of liver regeneration (Figure 1).

2.1. TNFα/NFκB Signaling Pathway. TNFα is a crucial cytokine during the priming phase of liver regeneration and activates the NFκB transcription factor via the TNF receptor 1 (TNFR1) in hepatocytes [42]. After partial hepatectomy, the production of TNFα is upregulated mainly in Kupffer cells; NFκB is activated within 30 minutes after partial hepatectomy, and the activation usually lasts no longer than 4–5 hours [1, 43]. During hepatocyte proliferation, NFκB is a heterodimer composed of two subunits, p65 and p50, which are assembled in the cytosol; the complex is inactivated by inhibitor of NFκB (IκB), which binds to the p65 subunit. After stimulation with TNFα, NFκB is activated by the removal of IκB from its p65 subunit; the activated NFκB then migrates to the cell nucleus, which regulates the G0/G1-to-S phase transition [44–46]. It was reported that the administration of a TNFα antibody or the knockout of TNFR1 in mice results in delayed liver regeneration after partial hepatectomy [8, 47]. In Kupffer cell-depleted mice, liver regeneration was impaired because of the loss of TNFα and NFκB [48].

2.2. IL-6/STAT3 Signaling Pathway. The STAT3 pathway, which is activated by such cytokines as IL-6, is known to play a crucial role in cell proliferation [49, 50]. Hepatocytes express TNFR1 on their surface and activate themselves in an autocrine fashion. Because the promoter region of the IL-6 gene contains the NFκB-binding site, IL-6 can also be produced by the activated Kupffer cells [51]. Recently, both LSECs and Kupffer cells were reported to produce IL-6 after hepatectomy [20, 33]. IL-6 binding causes the dimerization of gp130, which is the ubiquitously expressed signaling receptor molecule for the IL-6 family, and the activation of the intracellular tyrosine kinase that phosphorylates gp130 and creates the docking site of STAT3 [52]. STAT3 is then phosphorylated and translocates to the nucleus. STAT3 is activated slower than NFκB, becoming detectable at 1 to 2 hours after partial hepatectomy and lasting approximately 4–6 hours [1]. It was reported that hepatocytic mitosis in STAT3-knockout mice was significantly suppressed during liver regeneration after partial hepatectomy [53].

2.3. PI3K/Akt Signaling Pathway. The PI3K/Akt pathway has been known as a survival pathway functioning in antiapoptosis [54–56]. Recently, it was revealed that the PI3K/Akt pathway is responsible for regulating cell growth and determining cell size and functions [57–62]. In addition, Akt and downstream signals cause the compensatory hypertrophy of hepatocytes when cell proliferation is impaired [49]. The pathway is initiated by the activation of receptor tyrosine kinases or G protein-coupled receptors by HGF, IL-6, TNFα, TGFα, and many other signaling molecules [63–67]. HGF is a potent growth factor that is mainly derived from LSECs and activated HSCs and promotes proliferation and DNA synthesis in hepatocytes in a paracrine fashion [20, 68]. C-met is a tyrosine kinase receptor on the surface of hepatocytes that binds to HGF, and HGF/c-met signaling activates PI3K, which then recruits Akt to the site of membranes and subsequently phosphorylates Akt [65, 69, 70].
Phosphorylated Akt activates glycogen synthase kinase 3β (GSK3β), which induces DNA synthesis and cellular mitosis in hepatocytes [49, 71]. Furthermore, other downstream Akt factors, such as, mTOR and p70S6K, play critical roles in liver regeneration by regulating cell growth in addition to activated GSK3β [49, 60, 61]. It was reported that the specific PI3K inhibitor LY294002 abolished DNA synthesis in growth factor-stimulated hepatocytes [72].

2.4. MAPK/ERK Signaling Pathway. Once the MAPK/ERK pathway has been activated, ERK translocates to the nucleus.
where it can regulate the transcriptional activity of many immediate early genes [73]. The signaling cascade is activated by growth factors, such as, IGF-1 and EGF and is involved in the regulation of G1 phase progression during liver regeneration in vivo and in hepatocyte proliferation in vitro [13, 74–76]. In particular, IGF-1 signals activate both the PI3K/Akt and MAPK/ERK pathways, leading to the control of genes involved in hepatocyte proliferation and in protecting against apoptotic cell death [77].

3. Roles of Platelets in Liver Regeneration

It is known that platelets release local mediators and interact with leukocytes and endothelial cells to modulate inflammatory responses [78]. Platelets are involved in wound healing and tissue repair in addition to hemostasis and inflammation and can be associated with liver regeneration or tissue repair in liver injury. Platelets contain both the proteins needed for hemostasis and also many growth factors, such as, PDGF, HGF, IGF, VEGF, EGF, and TGFβ, which are required for tissue regeneration [23–29, 79–81]. In addition, platelets also contain certain cytokines, serotonin and lipid mediators, such as, S1P, ADP, and ATP [79, 82–84]. We previously reported on the relationship between platelets, nonparenchymal cells and hepatocytes during liver regeneration [23, 31, 33, 35] (Figure 1).

3.1. Direct Effect on Hepatocytes. We previously reported that platelets have a potent role in promoting liver regeneration after partial hepatectomy in mice by activating the Akt and ERK signaling pathways and stimulating hepatocyte proliferation in vitro [23, 31]. It is clear that the number of platelets affects liver regeneration during the priming phase after hepatectomy [31, 33, 85, 86]. As observed by transmission electron microscopy, some platelets were found to translocate into Disse’s spaces through the fenestration of LSECs and had direct contact with hepatocytes [31], which is similar to wound healing in which platelets become activated and release essential growth factors and cytokines by contact with collagen and other extracellular matrixes [79]. We previously reported that, when platelets and hepatocytes were separated by a permeable membrane, the platelets had no proliferative effect on the hepatocytes, suggesting that the direct contact between the cells was essential for inducing hepatocyte proliferation [23]. Growth factors in platelets, such as, IGF-1 and HGF, activated the Akt and ERK1/2 pathways and caused a proliferative effect on hepatocytes [23]. As it was reported that human platelets do not contain a significant amount of HGF, IGF-1 is the most important mediator for liver regeneration in humans [23, 87]. Platelets did not exert a proliferative effect on hepatocytes in the presence of LY294002, which inhibits the activation of the Akt pathway, suggesting that the Akt pathway is an important signal and that the activators of the Akt pathway are key molecules involved in the direct proliferative effect by platelets [23]. Furthermore, even under conditions of Kupffer cell depletion, platelets had a strong effect in hepatocyte proliferation through the phosphorylation of Akt, suggesting that Akt activation could compensate for liver regeneration when the TNFα/NFκB pathway derived from Kupffer cells was impaired [33].

3.2. Relationship between Platelets and Nonparenchymal Cells. Nonparenchymal cells in the liver, including Kupffer cells, LSECs, and hepatic stellate cells, are involved in the process of liver regeneration [36]. Because Kupffer cells are close to hepatocytes, the release of these mediators after partial hepatectomy may initiate the liver regeneration process [8, 88, 89]. Kupffer cells produce inflammatory cytokines, such as, TNFα and IL-6, and such growth factors as IGF-1 are generally presumed to be an important source of hepatic TNFα, which is a key component in the process of hepatocyte proliferation during liver regeneration [42, 90]. The depletion of Kupffer cells was reported to result in delayed liver regeneration because of the loss of TNFα and NFκB and the decrease of IGF-1 [33, 48, 91]. LSECs, which comprise 70% of the sinusoidal cells in the liver, are known to produce immunoregulatory and proinflammatory cytokines, including HGF, IL-6, interleukin-1, and interferon [20, 92, 93]. Under conditions of Kupffer cell depletion, the phosphorylation of STAT3 was detected in the regenerating liver after hepatectomy, suggesting that IL-6 could be produced by LSECs (instead of Kupffer cells) at a sufficient level to activate STAT3 [33]. We previously reported that platelets could function in collaboration with nonparenchymal cells during liver regeneration [33–35].

3.2.1. Relationship between Platelets and Kupffer Cells. Kupffer cells can be associated with the accumulation of platelets in the liver, which induces liver regeneration [33, 34]. It was reported that platelet accumulation in the liver after hepatectomy or other types of liver injury, such as, ischemic reperfusion or lipopolysaccharide administration, depended to some extent on Kupffer cells [31, 34, 94, 95]. Platelets in the liver sinusoids were mostly surrounded by the well-developed cell processes of Kupffer cells without phagocytosis [34]. Furthermore, the depletion of Kupffer cells resulted in the abolition of the accumulation and the migration of platelets in the liver [33, 34]. These results indicated that the cellular interactions between platelets and Kupffer cells play important roles in platelet behavior in the liver. In thrombocytosis, more platelets were recruited into the liver, providing high levels of IGF-1 and HGF, which induced the subsequent activation of downstream signal transductions, such as, the PI3K/Akt and MAPK/ERK pathways and advanced hepatocyte mitosis [33].

3.2.2. Relationship between Platelets and LSECs. We previously reported that platelets induced hepatocyte proliferation through LSEC activation [35]. Direct contact between platelets and LSECs triggered the secretion of S1P from the platelets, which induced the secretion of IL-6 from the LSECs; thereafter, the increase of IL-6 caused the activation of the STAT3 pathway in hepatocytes, Akt and ERK1/2 activation and the promotion of hepatocyte proliferation [35]. In addition, platelets caused the proliferation of LSECs.
and induced the secretion VEGF and IL-6 from the LSECs by activating the Akt and ERK1/2 pathways [35].

4. Conclusion

The liver is a vital organ in which the mechanisms of regeneration are orchestrated by a complex network of cytokines and growth factors. Nonparenchymal cells in the liver, such as, Kupffer cells, LSECs, and hepatic stellate cells, participate in liver regeneration with respect to both their own proliferation and effects on hepatocyte proliferation [19, 20]. Platelets contain various types of growth factors and cytokines and comprise another important factor involved in liver regeneration [23, 31]. In summary, platelets have a direct effect on stimulating hepatocyte proliferation and cooperative with Kupffer cells and LSECs during liver regeneration.

References

[1] G. K. Michalopoulos and M. C. DeFrances, “Liver regeneration,” Science, vol. 276, no. 5309, pp. 60–65, 1997.

[2] N. Fausto, “Liver regeneration: from laboratory to clinic,” Liver Transplantation, vol. 7, no. 10, pp. 835–844, 2001.

[3] P. S. Pahlavan, R. E. Feldmann Jr., C. Zavos, and J. Kountouras, “Prometheus’ challenge: molecular, cellular and systemic aspects of liver regeneration,” Journal of Surgical Research, vol. 134, no. 2, pp. 238–251, 2006.

[4] K. Shirabe, M. Shimada, T. Gion et al., “Postoperative liver failure after major hepatic resection for hepatocellular carcinoma in the modern era with special reference to remnant liver volume,” Journal of the American College of Surgeons, vol. 188, no. 3, pp. 304–309, 1999.

[5] B. Topal, L. Kaufman, R. Aerts, and F. Penninckx, “Patterns of failure following curative resection of colorectal liver metastases,” European Journal of Surgical Oncology, vol. 29, no. 3, pp. 248–253, 2003.

[6] A. Zimmermann, “Regulation of liver regeneration,” Nephrology Dialysis Transplantation, vol. 19, no. 4, pp. iv6–iv10, 2004.

[7] E. Galun and J. H. Axelrod, “The role of cytokines in liver injury and regeneration,” Seminars in Thrombosis and Hemostasis, vol. 5, no. 10, pp. 836–838, 2005.

[8] P. Akerman, P. Cote, Shi Qi Yang et al., “Antibodies to tumor necrosis factor-α inhibit liver regeneration after partial hepatectomy,” American Journal of Physiology, vol. 263, no. 4, pp. G579–G585, 1992.

[9] R. A. DeAngelis, K. Kovalovich, D. E. Cressman, and R. Taub, “Normal liver regeneration in p50/ nuclear factor κB knockout mice,” Hepatology, vol. 33, no. 4, pp. 915–924, 2001.

[10] A. Blidenbacher, X. Wang, I. Langer, R. Savino, L. Terracciano, and M. H. Heim, “Interleukin 6 is important for survival after partial hepatectomy in mice,” Hepatology, vol. 38, no. 3, pp. 674–682, 2003.

[11] W. Li, X. Liang, C. Kellendonk, V. Poli, and R. Taub, “STAT3 contributes to the mitogenic response of hepatocytes during liver regeneration,” Journal of Biological Chemistry, vol. 277, no. 32, pp. 28411–28417, 2002.

[12] A. Behrens, M. Sibilia, J. P. David et al., “Impaired postnatal hepatocyte proliferation and liver regeneration in mice lacking c-jun in the liver,” The EMBO Journal, vol. 21, no. 7, pp. 1782–1790, 2002.

[13] H. Talarmin, C. Rescan, S. Cariou et al., “The mitogen-activated protein kinase extracellular signal-regulated kinase cascade activation is a key signalling pathway involved in the regulation of G1 phase progression in proliferating hepatocytes,” Molecular and Cellular Biology, vol. 19, no. 9, pp. 6003–6011, 1999.

[14] M. S. Spector, K. L. Auer, W. D. Jarvis et al., “Differential regulation of the mitogen-activated protein and stress-activated protein kinase cascades by adrenergic agonists in quiescent and regenerating adult rat hepatocytes,” Molecular and Cellular Biology, vol. 17, no. 7, pp. 3556–3565, 1997.

[15] F. Hong, V. A. Nguyen, X. Shen, G. Kunos, and B. Gao, “Rapid activation of protein kinase B/Akt has a key role in antiapoptotic signaling during liver regeneration,” Biochemical and Biophysical Research Communications, vol. 279, no. 3, pp. 974–979, 2000.

[16] M. Borowiak, A. N. Garratt, T. Wustefeld, M. Strehe, C. Trautwein, and C. Birchmeier, “Met provides essential signals for liver regeneration,” Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 29, pp. 10608–10613, 2004.

[17] N. Fausto, A. D. Laird, and E. M. Webber, “Role of growth factors and cytokines in hepatic regeneration,” The FASEB Journal, vol. 9, no. 15, pp. 1527–1536, 1995.

[18] B. Gao, W. I. Jeong, and Z. Tian, “Liver: an organ with predominant innate immunity,” Hepatology, vol. 47, no. 2, pp. 729–736, 2008.

[19] M. Granado, A. I. Martin, T. Priego, M. A. Villanúa, and A. López-Calderón, “Inactivation of Kupffer cells by gadolinium administration prevents lipopolysaccharide-induced decrease in liver insulin-like growth factor-1 and IGF-binding protein-3 gene expression,” Journal of Endocrinology, vol. 188, no. 3, pp. 503–511, 2006.

[20] C. Ping, D. Xiaoling, Z. Jin, D. Jiahong, D. Jiming, and Z. Lin, “Hepatic sinusoidal endothelial cells promote hepatocyte proliferation early after partial hepatectomy in rats,” Archives of Medical Research, vol. 37, no. 5, pp. 576–583, 2006.

[21] R. Taub, “Liver regeneration: from myth to mechanism,” Nature Reviews Molecular Cell Biology, vol. 5, no. 10, pp. 836–847, 2004.

[22] T. Lisman and R. J. Porte, “The role of platelets in liver regeneration,” Cell, vol. 263, no. 4, pp. 279–286, 2008.

[23] R. Matsuo, N. Ohkohchi, S. Murata et al., “Platelets strongly induce hepatocyte proliferation with IGF-1 and HGF in vitro,” The Journal of Surgical Research, vol. 145, no. 2, pp. 279–286, 2008.

[24] E. W. Raines and R. Ross, “Purification of human platelet-derived growth factor,” Methods in Enzymology, vol. 109, pp. 749–773, 1985.

[25] Y. Hiyama, I. Mahmud, and F. Karimi-Tari, “Platelet-derived growth factor and thromboxane are necessary for liver regeneration,” Cellular and Molecular Biology, vol. 27, no. 6, pp. 593–599, 1981.

[26] T. Nakamura, H. Teramoto, and A. Ichihara, “Purification and characterization of a growth factor from rat platelets for mature parenchymal hepatocytes in primary cultures,” Proceedings of the National Academy of Sciences of the United States of America, vol. 83, no. 17, pp. 6489–6493, 1986.

[27] T. Nakamura, K. Nawa, A. Ichihara, N. Kaise, and T. Nishino, “Purification and subunit structure of hepatocyte growth factors and cytokines in hepatic regeneration.”
factor from rat platelets,” *FEBS Letters*, vol. 224, no. 2, pp. 311–316, 1987.

[28] R. K. Assoian, A. Komoriya, and C. A. Meyers, “Transforming growth factor-β in human platelets. Identification of a major storage site, purification, and characterization,” *Journal of Biological Chemistry*, vol. 258, no. 11, pp. 7155–7160, 1983.

[29] Y. Oka and D. N. Orth, “Human plasma epidermal growth factor/β-urogastrone is associated with blood platelets,” *The Journal of Clinical Investigation*, vol. 72, no. 1, pp. 249–259, 1983.

[30] M. Lesurtel, R. Graf, B. Aleil et al., “Platelet-derived serotonin storage site, purification, and characterization,” *World Journal of Surgery*, vol. 31, no. 4, pp. 808–816, 2007.

[31] S. Murata, N. Ohkohchi, R. Matsuo, O. Ikeda, A. Myronovych, and R. Hoshi, “Platelets promote liver regeneration in early period after hepatectomy in mice,” *Journal of Biological Chemistry*, vol. 104, no. 3, pp. 363–372, 2008.

[32] S. Murata, R. Matsuo, O. Ikeda et al., “Platelets promote liver regeneration under conditions of Kupffer cell depletion after hepatectomy in mice,” *World Journal of Surgery*, vol. 32, no. 6, pp. 1088–1096, 2008.

[33] M. Nakamura, M. Shibazaki, Y. Nitta, and Y. Endo, “Translocation of platelets into Dise spaces and their entry into hepatocytes in response to lipopolysaccharides, interleukin-1 and tumour necrosis factor: the role of Kupffer cells,” *Journal of Hepatology*, vol. 28, no. 6, pp. 991–999, 1998.

[34] T. Kawasaki, S. Murata, K. Takahashi et al., “Activation of human liver sinusoidal endothelial cell by human platelets induces hepatocyte proliferation,” *Journal of Hepatology*, vol. 53, no. 4, pp. 648–654, 2010.

[35] R. Malik, C. Selden, and H. Hodgson, “The role of non-parenchymal cells in liver growth,” *Seminars in Cell and Developmental Biology*, vol. 13, no. 6, pp. 425–431, 2002.

[36] G. L. Wang, E. Salisbury, X. Shi, L. Timchenko, E. E. Medrano, and N. A. Timchenko, “HDAC1 promotes liver proliferation in young mice via interactions with C/EBPβ,” *Molecular and Cellular Biology*, vol. 283, no. 38, pp. 26179–26187, 2008.

[37] M. J. FitzGerald, E. M. Webber, J. R. Donovan, and N. Fausto, “Rapid DNA binding by nuclear factor xB in hepatocytes at the start of liver regeneration,” *Cell Growth and Differentiation*, vol. 6, no. 4, pp. 417–427, 1995.

[38] A. Moh, Y. Iwamoto, G. X. Chai et al., “Role of STAT3 in liver regeneration: survival, DNA synthesis, inflammatory reaction and liver mass recovery,” *Laboratory Investigation*, vol. 87, no. 10, pp. 1018–1028, 2007.

[39] B. D. Manning and L. C. Cantley, “AKT/PKB signaling: navigating downstream,” *Cell*, vol. 129, no. 7, pp. 1261–1274, 2007.

[40] G. L. Johnson and R. Lapadat, “Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases,” *Science*, vol. 298, no. 5600, pp. 1911–1912, 2002.

[41] Y. Yamada, I. Kirillova, J. J. Peschon, and N. Fausto, “Initiation of liver growth by tumor necrosis factor: deficient liver regeneration in mice lacking type I tumor necrosis factor receptor,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 94, no. 4, pp. 1441–1446, 1997.

[42] L. Yang, S. T. Magness, R. Bataller, R. A. Rippe, and D. A. Brenner, “NF-κB activation in Kupffer cells after partial hepatectomy,” *American Journal of Physiology*, vol. 289, no. 3, pp. G530–G538, 2005.

[43] Y. Yamada, E. M. Webber, I. Kirillova, J. J. Peschon, and N. Fausto, “Analysis of liver regeneration in mice lacking type I or type 2 tumor necrosis factor receptor: requirement for type I but not type 2 receptor,” *Hepatology*, vol. 28, no. 4, pp. 959–970, 1998.

[44] L. Solt and M. J. May, “The IκB kinase complex: master regulator of NF-κB signaling,” *Immunologic Research*, vol. 42, no. 1–3, pp. 3–18, 2008.

[45] M. Hinz, D. Krappmann, A. Eichten, A. Heder, C. Scheiderreit, and M. Strauss, “NF-κB function in growth control: regulation of cyclin D1 expression and G0/G1-to-S-phase transition,” *Molecular and Cellular Biology*, vol. 19, no. 4, pp. 2690–2698, 1999.

[46] S. Devi and H. M. Mehendale, “The role of NF-κB signaling in impaired liver tissue repair in thioacetamide-treated type 1 diabetic rats,” *European Journal of Pharmacology*, vol. 523, no. 1–3, pp. 127–136, 2005.

[47] Y. Yamada, E. M. Webber, I. Kirillova, J. J. Peschon, and N. Fausto, “Analysis of liver regeneration in mice lacking type 1 or type 2 tumor necrosis factor receptor: requirement for type I but not type 2 receptor,” *Hepatology*, vol. 28, no. 4, pp. 959–970, 1998.

[48] K. Abshagen, C. Eipel, J. C. Kalf, M. D. Menger, and B. Vollmar, “Loss of NF-κB activation in Kupffer cell-depleted mice impairs liver regeneration after partial hepatectomy,” *American Journal of Physiology*, vol. 292, no. 6, pp. G1570–G1577, 2007.

[49] S. Haga, W. Ogawa, H. Inoue et al., “Compensatory recovery of liver mass by Akt-mediated hepatocellular hypertrophy in liver-specific STAT3-deficient mice,” *Journal of Hepatology*, vol. 43, no. 5, pp. 799–807, 2005.

[50] D. E. Levy and C. K. Lee, “What does Stat3 do?” *Journal of Clinical Investigation*, vol. 109, no. 9, pp. 1143–1148, 2002.

[51] T. A. Libermann and D. Baltimore, “Activation of interleukin-6 gene expression through the NF-κB transcription factor,” *Molecular and Cellular Biology*, vol. 10, no. 5, pp. 2327–2334, 1990.

[52] P. C. Heinrich, I. Behrmann, G. Muller-Newen, F. Schaper, and L. Graebe, “Interleukin-6-type cytokine signalling through the gp130/jak/STAT pathway,” *Biochemical Journal*, vol. 334, no. 2, pp. 297–314, 1998.

[53] S. Haga, M. Ozaki, H. Inoue et al., “The survival pathways phosphatidylinositol-3 kinase (PI3-K)/phosphoinositide-dependent protein kinase 1 (PDK1)/Akt modulate liver regeneration through hepatocyte size rather than proliferation,” *Hepatology*, vol. 49, no. 1, pp. 204–214, 2009.

[54] Y. Tanaka, M. V. Gavrilides, Y. Mitsuuchi, T. Fujii, and M. G. Kazanietz, “Protein kinase C promotes apoptosis in LNCaP prostate cancer cells through activation of p38 MAPK and inhibition of the Akt survival pathway,” *The Journal of Biological Chemistry*, vol. 278, no. 36, pp. 33753–33762, 2003.

[55] A. R. Conery, Y. Cao, E. A. Thompson, C. M. Townsend, T. C. Ko, and K. Luo, “Akt interacts directly with Smad3 to regulate the sensitivity to TGF-β-induced apoptosis,” *Nature Cell Biology*, vol. 6, no. 4, pp. 366–372, 2004.

[56] S. J. Gardai, D. A. Hildeman, S. K. Frankel et al., “Phosphorylation of Bax ser184 by Akt regulates its activity and apoptosis in neutrophils,” *Journal of Biological Chemistry*, vol. 279, no. 20, pp. 21085–21095, 2004.

[57] M. Pende, S. C. Kozma, M. D. Menghi et al., “Hypoinsulinaemia, glucose intolerance and diminished β-cell size in S6K1-deficient mice,” *Nature*, vol. 408, no. 6815, pp. 994–997, 2000.

[58] A. L. Edinger and C. B. Thompson, “Akt maintains cell size and survival by increasing mTOR-dependent nutrient uptake,” *Molecular Biology of the Cell*, vol. 13, no. 7, pp. 2276–2288, 2002.

[59] M. G-Amlak, S. Uddin, D. Mahmud et al., “Regulation of myeloma cell growth through Akt/Gsk3/forkhead signaling
pathway,” *Biochemical and Biophysical Research Communications*, vol. 297, no. 4, pp. 760–764, 2002.

[60] J. Faridi, J. Fawcett, L. Wang, and R. A. Roth, “Akt promotes increased mammalian cell size by stimulating protein synthesis and inhibiting protein degradation,” *American Journal of Physiology*, vol. 285, no. 5, pp. E964–E972, 2003.

[61] M. V. G. Latronico, S. Costinean, M. L. Lavitrano, C. Peschle, and G. Condorelli, “Regulation of cell size and contractile function by Akt in cardiomyocytes,” *Annals of the New York Academy of Sciences*, vol. 1015, pp. 250–260, 2004.

[62] P. M. Mourani, P. J. Garl, J. M. Wenzlau, T. C. Carpenter, K. R. Stenmark, and M. C. M. Weiser-Evans, “Unique, highly proliferative growth phenotype expressed by embryonic and neonatal smooth muscle cells is driven by constitutive Akt, mTOR, and p70S6K signaling and is actively repressed by PTEN,” *Circulation*, vol. 109, no. 10, pp. 1299–1306, 2004.

[63] Y. Osawa, M. Nagaki, Y. Banno et al., “Tumor necrosis factor alpha-induced interleukin-8 production via NF-κB factor alpha-induced interleukin-8 production via NF-κB,” *Infection and Immunity*, vol. 70, no. 11, pp. 6294–6301, 2002.

[64] J. Okano, G. Shiota, K. Matsumoto et al., “Hepatocyte growth factor/c-met proto-oncogene product, but not with H-ras mutations, and phosphorylation of ERK2 knockdown approach in wild-type and ERK1 null hepatocytes,” *Hepatology*, vol. 45, no. 4, pp. 1035–1045, 2007.

[65] J. P. Rao, E. J. Studer, R. T. Stravitz et al., “Activation of the Raf-1/MEK/ERK cascade by bile acids occurs via the epidermal growth factor receptor in primary rat hepatocytes,” *Hepatology*, vol. 35, no. 2, pp. 307–314, 2002.

[66] L. S. Nilssen, G. H. Thoresen, T. Christoffersen, and D. Sandnes, “Differential role of MAP kinases in stimulation of hepatocyte growth by EGF and G-protein-coupled receptor agonists,” *Biochemical and Biophysical Research Communications*, vol. 291, no. 3, pp. 588–592, 2002.

[67] J. Dupont and D. LeRoith, “Insulin and insulin-like growth factor I receptors: similarities and differences in signal transduction,” *Hormone Research*, vol. 55, no. 2, pp. 22–26, 2001.

[68] G. Bazzoni, E. Dejana, and A. Del Maschio, “Platelet-neutrophil interactions. Possible relevance in the pathogenesis of thrombosis and inflammation,” *Haematologica*, vol. 76, no. 6, pp. 491–499, 1991.

[69] R. F. Diegelmann and M. C. Evans, “Wound healing: an overview of acute, fibroitic and delayed healing,” *Frontiers in Bioscience*, vol. 9, pp. 283–289, 2004.

[70] R. Gruber, M. Baron, D. Busenlechner, B. Kandler, G. Fuerst, and G. Watzek, “Proliferation and osteogenic differentiation of cells from cortical bone cylinders, bone particles from mill, and drilling dust,” *Journal of Oral and Maxillofacial Surgery*, vol. 63, no. 2, pp. 238–243, 2005.

[71] D. Gerard, E. R. Carlson, J. E. Gotcher, and M. Jacobs, “Effects of platelet-rich plasma on the healing of autologous bone grafted mandibular defects in dogs,” *Journal of Oral and Maxillofacial Surgery*, vol. 64, no. 3, pp. 443–451, 2006.

[72] E. Cenni, D. Granchi, M. Vancini, and A. Pizzoferrato, “Platelet release of transforming growth factor-β and β-thromboglobulin after in vitro contact with acrylic bone cements,” *Biomaterials*, vol. 23, no. 6, pp. 1479–1484, 2002.

[73] E. Cenni, D. Granchi, and A. Pizzoferrato, “Platelet activation after in vitro contact with seven acrylic bone cements,” *Journal of Biomaterials Science, Polymer Edition*, vol. 13, no. 1, pp. 17–25, 2002.

[74] S. Spiegel and S. Milstien, “Sphingosine-1-phosphate: an enigmatic signalling lipid,” *Nature Reviews Molecular Cell Biology*, vol. 4, no. 5, pp. 397–407, 2003.

[75] S. Murata, I. Hashimoto, Y. Nakano, A. Myronovych, M. Watanabe, and N. Ohkohchi, “Single administration of thrombopoietin prevents progression of liver fibrosis and promotes liver regeneration after partial hepatectomy in cirrhotic rats,” *Annals of Surgery*, vol. 248, no. 5, pp. 821–828, 2008.

[76] R. Matsuo, Y. Nakano, and N. Ohkohchi, “Platelet administration via the portal vein promotes liver regeneration in rats after 70% hepatectomy,” *Annals of Surgery*, vol. 253, no. 4, pp. 759–763, 2011.

[77] T. Nakamura, T. Nishizawa, M. Hagiya et al., “Platelet adhesion to collagen type I receptors: similarities and differences in acute, fibroitic and delayed healing,” *Hepatology*, vol. 342, no. 6248, pp. 440–443, 1989.

[78] A. Coutant, C. Recan, D. Gilot, P. Loyer, C. Guguen-Guillouzo, and G. Baffet, “PTEN/FRA1/mTOR pathway is critical for hepatocyte proliferation whereas MEK/ERK supports both proliferation and survival,” *Hepatology*, vol. 36, no. 5, pp. 1079–1088, 2002.

[79] R. Treisman, “Regulation of transcription by MAP kinase cascades,” *Current Opinion in Cell Biology*, vol. 8, no. 2, pp. 205–215, 1996.

[80] C. Frémin, F. Ezan, P. Boisselier et al., “ERK2 but not ERK1 plays a key role in hepatocyte replication: an RNAi-mediated pathway,” *Biochemical and Biophysical Research Communications*, vol. 297, no. 4, pp. 760–764, 2002.
liver injury,” *American Journal of Physiology*, vol. 267, no. 4, pp. G552–G561, 1994.

[91] C. Meijer, M. J. Wiezer, A. M. Diehl et al., “Kupffer cell depletion by CI2MDP-liposomes alters hepatic cytokine expression and delays liver regeneration after partial hepatectomy,” *Liver*, vol. 20, no. 1, pp. 66–77, 2000.

[92] D. L. Knook and E. C. Sleyster, “Separation of Kupffer and endothelial cells of the rat liver by centrifugal elutriation,” *Experimental Cell Research*, vol. 99, no. 2, pp. 444–449, 1976.

[93] B. Smedsrod, H. Pertoft, S. Gustafson, and T. C. Laurent, “Scavenger functions of the liver endothelial cell,” *The Biochemical Journal*, vol. 266, no. 2, pp. 313–327, 1990.

[94] Y. Endo and M. Nakamura, “The effect of lipopolysaccharide, interleukin-1 and tumour necrosis factor on the hepatic accumulation of 5-hydroxytryptamine and platelets in the mouse,” *British Journal of Pharmacology*, vol. 105, no. 3, pp. 613–619, 1992.

[95] Y. Endo and M. Nakamura, “Active translocation of platelets into sinusoidal and Disse spaces in the liver in response to lipopolysaccharides, interleukin-1 and tumor necrosis factor,” *General Pharmacology*, vol. 24, no. 5, pp. 1039–1053, 1993.